NASDAQ · TBPH
Healthcare · Biotechnology
$17.01
Up+$0.06 (+0.35%)
Updated Aug 22, 2026, 6:23 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
TBPH closed at $17.01 after 21 trading sessions, up 0.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $16.97 | $17.02 | $16.96 | $17.01 | 739.34K |
| Aug 20, 2026 | $16.98 | $17.00 | $16.95 | $16.95 | 205.51K |
| Aug 19, 2026 | $16.96 | $17.00 | $16.96 | $16.99 | 257.86K |
| Aug 18, 2026 | $16.96 | $16.96 | $16.93 | $16.95 | 266.96K |
| Aug 17, 2026 | $16.97 | $16.97 | $16.92 | $16.92 | 297.17K |
| Aug 14, 2026 | $16.91 | $16.99 | $16.91 | $16.97 | 405.44K |
| Aug 13, 2026 | $16.94 | $16.94 | $16.90 | $16.92 | 358K |
| Aug 12, 2026 | $16.91 | $16.95 | $16.91 | $16.92 | 495.21K |
| Aug 11, 2026 | $16.91 | $16.96 | $16.90 | $16.92 | 952.37K |
| Aug 10, 2026 | $16.93 | $16.95 | $16.88 | $16.91 | 427.64K |
| Aug 7, 2026 | $16.92 | $16.95 | $16.91 | $16.93 | 2.72M |
| Aug 6, 2026 | $16.90 | $16.94 | $16.90 | $16.92 | 272.44K |
| Aug 5, 2026 | $16.90 | $16.91 | $16.86 | $16.90 | 400.38K |
| Aug 4, 2026 | $16.88 | $16.88 | $16.865 | $16.88 | 420.21K |
| Aug 3, 2026 | $16.86 | $16.88 | $16.86 | $16.87 | 437.74K |
| Jul 31, 2026 | $16.87 | $16.88 | $16.85 | $16.86 | 369.7K |
| Jul 30, 2026 | $16.86 | $16.87 | $16.84 | $16.85 | 398.14K |
| Jul 29, 2026 | $16.88 | $16.91 | $16.85 | $16.85 | 444.15K |
| Jul 28, 2026 | $16.92 | $16.92 | $16.88 | $16.89 | 257.59K |
| Jul 27, 2026 | $16.87 | $16.91 | $16.86 | $16.86 | 395.41K |
| Jul 24, 2026 | $16.90 | $16.91 | $16.83 | $16.86 | 652.2K |
The latest Smart Investors Daily articles mentioning TBPH.
TBPH research
Company profile and research snapshot.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 7, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 29, 2026 | BTIG | Neutral | — |
| Jun 29, 2026 | Jones Trading | Hold | — |
| Apr 7, 2026 | B. Riley Securities | Neutral | — |
| Mar 23, 2026 | TD Cowen | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent. This is a 325 percent increase over losses of $(0.08) per share from
Benzinga · Jul 7, 2026
HC Wainwright & Co. analyst Douglas Tsao downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral and raises the price target from $15 to $17.
SeekingAlpha · Jul 1, 2026
Zymeworks (ZYME) buys Theravance for $929M, adding Yupelri royalties and cash flow through 2039.
Benzinga · Jun 29, 2026
Jones Trading analyst Debanjana Chatterjee downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Hold.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TBPH.
